Drug Approval | February 23, 2023
Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
Subscribe To Our Newsletter & Stay Updated
